Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs with Moderately to Severely Active Rheumatoid Arthritis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs with Moderately to Severely Active Rheumatoid Arthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms RA-BUILD
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 15 Jun 2019 Results of pooled analysis from nine studies of Baricitinib treated rheumatoid arthritis patients presented at the 20th Annual Congress of the European League Against Rheumatism
    • 06 Jun 2019 According to an Eli Lilly media release, data from this trial will be presented at the upcoming Annual European Congress of Rheumatology (EULAR 2019) in Madrid from June 12-15, 2019.
    • 06 Mar 2019 Results of post-hoc pooled analysis of 5 trials (NCT01185353, NCT01469013, NCT00902486, NCT01710358 and NCT01721057) and an ongoing open-label, long-term extension (LTE) study ( NCT01885078), studying effect of select comorbidities on the efficacy and safety of baricitinib 4 mg once daily in patients with moderate-to-severe active RA published in the Annals of the Rheumatic Diseases.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top